Welcome to our dedicated page for GNBT news (Ticker: GNBT), a resource for investors and traders seeking the latest updates and insights on GNBT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GNBT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GNBT's position in the market.
Generex Biotechnology Corporation's majority-owned subsidiary, NuGenerex Immuno-Oncology, is advancing the Ii-Key-SARS-CoV-2 vaccine aimed at children and pregnant women. The vaccine utilizes natural amino acids without genetic material, addressing the unmet need for safe COVID-19 vaccination in these populations. The company plans to submit an FDA IND to initiate clinical trials by Fall 2021. Recognized for its safety in previous trials, this vaccine represents a promising option as schools reopen and vaccination efforts escalate. Fundraising efforts are underway to support clinical trials and ensure vaccine accessibility.
Generex Biotechnology Corporation (OTCQB: GNBT) announced a shareholder conference call on May 6, 2021, at 9:00 AM ET. CEO Joseph Moscato will discuss recent corporate developments, including advancements in the FDA IND submission for their Complete Vaccine against SARS-CoV-2, which has completed GMP manufacturing for human trials. He will also provide updates on partnerships in Malaysia and China, as well as the status of NuGenerex Immuno-Oncology's NASDAQ listing application. The call will include a Q&A session for shareholders.
Generex Biotechnology Corporation (OTCQB: GNBT) announced successful results from an immunogenicity study of its Ii-Key-SARS-CoV-2 vaccine in transgenic mice. The vaccine elicited strong CD4+ and CD8+ T cell responses, indicating potential for long-term immunity. The company plans to submit an IND for Phase I and II human clinical trials soon. Additionally, discussions are underway to license therapeutic antibodies from a major research institution for COVID-19 treatment, indicating a potential expansion of its therapeutic portfolio.
Generex Biotechnology Corporation (OTCQB:GNBT) announced details for its investor conference call scheduled for February 5, 2021, at 9:00 AM. Key topics include updates on the Ii-Key-SARS-CoV-2 vaccine program and a $1 million advance on a China licensing agreement. CEO Joe Moscato will discuss recent developments, including GMP production of the vaccine and ongoing clinical studies. The company is also exploring licensing opportunities for COVID-19 therapeutic antibodies. Stakeholders can join the call using provided dial-in information.
Generex Biotechnology Corporation (OTCQB:GNBT) announces the publication of a peer-reviewed article on therapeutic cancer vaccines in the journal Cancers. The article emphasizes the significance of optimal clinical trial design, including patient selection and follow-up periods, to assess treatment efficacy. It details findings from the Phase IIb trial of AE37 in breast cancer, highlighting a survival benefit for specific patient subgroups. The company plans future trials, including one for bladder cancer, to further explore the potential of its Ii-Key immunotherapeutic vaccines.
Generex Biotechnology Corporation (OTCQB:GNBT) announced an investor conference call on Thursday, October 8, 2020, at 8:00 AM Eastern time. Key topics include a licensing agreement with Bintai Kinden for a COVID-19 vaccine and updates on ongoing initiatives. CEO Joseph Moscato will discuss plans for the listing of NuGenerex Immuno-Oncology and advancements in their Ii-Key technology platform. Generex emphasizes their focus on generating immunotherapies and vaccines, particularly in response to the pandemic's challenges.
Generex Biotechnology Corporation (GNBT) has finalized a licensing and distribution agreement with Bintai Kinden Corporation to develop and commercialize the Ii-Key-SARS-CoV-2 vaccine against COVID-19. Bintai will pay a $2.625 million upfront fee and fund all U.S. clinical trials, targeting revenues exceeding $1 billion from sales in Southeast Asia. The vaccine is priced at $3 per dose for governments and $4.50 commercially, allowing for exclusive distribution rights in Southeast Asia, Australia, and New Zealand. Generex aims to address the unmet need for safe vaccines in children and pregnant women.
Generex Biotechnology Corporation (OTCQB:GNBT) announced the formation of a COVID-19 Vaccine Scientific & Clinical Advisory Board (SAB) to oversee the development of the Ii-Key-SARS-CoV-2 vaccine, particularly for pediatric populations and pregnant women. Dr. Jonathan Davis and Dr. Gary Noel will co-chair the pediatric panel, while Dr. John Sanders will chair the adult panel. The company aims to leverage its peptide-based vaccine technology, which has shown safety in prior trials, to expedite clinical studies targeting these critical groups. CEO Joseph Moscato highlighted the urgency of addressing unmet needs in the pandemic.
Generex Biotechnology's subsidiary, NuGenerex Immuno-Oncology, announced the closing of a licensing and distribution agreement with Bintai for a COVID-19 vaccine in Malaysia. The company plans to update shareholders on the Ii-Key-SARS-CoV-2 vaccine development during a call on October 8th. CEO Joseph Moscato expressed optimism about expanding clinical development and commercialization efforts through partnerships. Furthermore, NuGenerex intends to apply for a Nasdaq listing, which could enhance value for Generex shareholders.
